Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 3, 2002 - Issue 7
Submit an article Journal homepage
169
Views
19
CrossRef citations to date
0
Altmetric
Miscellaneous

Advances in the treatment of rheumatoid arthritis: old versus new therapies

Jennifer Hamilton Queen Elizabeth Hospital, Gateshead, NE9 6SX, UK, Tel: +44 (0)191 403 6046;, Fax: +44 (0)191 403 2773;, E-mail: [email protected]
&
Vadivelu Saravanan Department of Rheumatology, James Cook University Hospital, Middlesbrough, UK
Pages 845-856 | Published online: 25 Feb 2005

Bibliography

  • WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of rheumatoid arthritis. Arthritis Rheum. (1994) 37:481–494.
  • O'DELL JR: Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum. (2002) 46:283–285.
  • FRIES JF: Reevaluating the therapeutic approach to rheumatoid arthritis: the 'saw tooth' strategy. J. Rheumatul (1990) 22(Suppl.):12–15.
  • EGSMOSE C, LUND B, BORG G et al:Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5-year follow-up of a prospective double blind placebo controlled study. J. Rheumatul (1995) 22:2208–2213.
  • MUNRO R, HAMPSON R, MCENTEGART A et al.: Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann. Rheum. Dis. (1998) 57:88–93.
  • SINGH G, FRIES JF, WILLIAMS CA et al.: Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. Rheumatul (1991) 18:188–194.
  • DEL RINCON ID, WILLIAMS K, STERN MP, FREEMAN GL, ESCALANTE A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. (2001) 44:2737–2745.
  • BACON PA, TOWNEND JN: Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum. (2001) 44:2707–2710.
  • WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl. J. Med. (1999) 340:1888–1899.
  • FRIES JF, WILLIAMS CA, BLOCH DA, MICHEL BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Jim. I Med. (1991) 91:213–222.
  • •Study of risk of serious GI events with NSAIDs in RA compared to OA.
  • SINGH G, TRIADAFILOPOULOS G: Epidemiology of NSAID induced gastrointestinal complications. Rheumatol (1999) 26(Suppl.):24.
  • WARD MM, FRIES JF: Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J. Rheumatol (1998) 25:408–416.
  • SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK: Management of early rheumatoid arthritis - a national clinical guideline (2000).
  • •National guidelines on management of early RA.
  • AMERICAN COLLEGE OF RHEUMATOLOGY SUBCOMMITTEE ON RHEUMATOID ARTHRITIS GUIDELINES: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritic Rheum. (2002) 46:328–346.
  • WONG WY, RICHARDS JS: Evidence fortwo antigenically distinct molecular weight variants of prostaglandin H synthase in the rat ovary. Ma Endocrinol. (1991) 5:1269–1279.
  • BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl. I Med. (2000) 343:1520–1528.
  • ••VIGOR - randomised, controlled trial ofrofecoxib in RA.
  • SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. "AMA (2000) 284:1247–1255.
  • ••CLASS - randomised, controlled trial ofcelecoxib in RA and OA.
  • ZHAO SZ, REYNOLDS MW, LEJKOWITH J, WHELTON A, ARELLANO FM: A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin. Therapeut. (2001) 23:1478–1491.
  • KONSTAM MA, WEIR MR, REICIN A et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 104:2280–2288.
  • NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE: Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis.(2001).
  • •British guidance on use of COX-2 selective drugs in RA and OA.
  • FRIES JF: ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System). Rheumatol (1995) 22:995–997.
  • FELSON DT, ANDERSON JJ, MEENAN RF: The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritic Rheum. (1994) 37:1487–1491.
  • COMBE B, DOUGADOS M, GOUPILLE P et al.: Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritic Rheum. (2001) 44:1736–1743.
  • •Study of prognostic factors in RA.
  • HARRISON BJ, SYMMONS DP, BRENNAN P et al: Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. J. Rheumatol (1996) 23:1326–1331.
  • ALBERT DA, AKSENTIJEVICH S, HURST S, FRIES JF, WOLFE F: Modeling therapeutic strategies in rheumatoid arthritis: use of decision analysis and Markov models. J. Rheumatol (2000) 27:644–652.
  • BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 350:309–318.
  • ••Step-down trial of methotrexate,sulfasalazine and steroids in early RA showing short-term benefit.
  • LANDEWE RBB, BOERS M, VERHOEVEN AC et al: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritic Rheum. (2002) 46:347-356. Long-term follow-up of the above step-down trial of methotrexate, sulfasalazine and steroids in early RA showing long-term benefit.
  • DOUGADOS M, COMBE B, CANTAGREL A et al.: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann. Rheum. Dis. (1999) 58:220–225.
  • HAAGSMA CJ, VAN RIEL PL, DE JONG AJ, VAN DE PUTTE LB: Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Rheumatol (1997) 36:1082–1088.
  • O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl. I Med. (1996) 334:1287–1291.
  • ••Combination trial of triple therapy withmethotrexate, sulfasalazine and hydroxychloroquine showing advantage over single therapy with methotrexate alone or sulfasalazine plus hydroxychloroquine combination.
  • TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl. J. Med. (1995) 333:137–141.
  • ••Addition of cydosporin when there is onlypartial response to methotrexate was shown to be of benefit in this trial.
  • WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritic Rheum. (1999) 42:1322–1328.
  • PINCUS T, O'DELL JR, KREMER JM:Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann. Intern. Med (1999) 131:768–774.
  • KLOPPENBURG M, BREEDVELD FC, TERWIEL JP, MALLEE C, DIJKMANS BA: Minocycline in active rheumatoid arthritis. A double-blind, placebo- controlled trial. Arthritis Rheum. (1994) 37:629–636.
  • O'DELL JR, HAIRE CE, PALMER W et al.: Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritic Rheum. (1997) 40:842–848.
  • O'DELL JR, BLAKELY KW, MALLEK JA et al.: Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum. (2001) 44:2235–2241.
  • ••Minocydine shown to be more beneficialthan hydroxychloroquine in this randomised, controlled trial in early RA.
  • TILLEY BC, ALARCON GS, HEYSE SP et al.: Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann. Intern. Med. (1995) 122:81–89.
  • KLOPPENBURG M, VERWEIJ CL, MILTENBURG AM et al.: The influence of tetracyclines on T cell activation. Clin. Exp. Immunol (1995) 102:635–641.
  • SAD OWSKI T, STEINMEYER J: Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm. Res. (2001) 50:175–182.
  • BREEDVELD FC, DAYER JM: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. (2000) 59:841–849.
  • CHERWINSKI HM, COHN RG, CHEUNG P et al.: The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. I Pharmacol Exp. Ther. (1995) 275:1043–1049.
  • CHONG AS, HUANG W, LIU Wet al: In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation. (1999) 68:100–109.
  • MANNA SK, MUKHOPADHYAY A, AGGARWAL BB: Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. Immunol (2000) 165:5962–5969.
  • COHEN S, CANNON GW, SCHIFF M et al.: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. (2001) 44:1984-1992. Randomised, controlled trial of leflunomide in RA was as effective as methotrexate.
  • EMERY P, BREEDVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (2000) 39:655–665.
  • ••Randomised, controlled trial of leflunomide in RA was as effective as methotrexate.
  • SCOTT DL, SMOLEN JS, KALDEN JR et al.: Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann. Rheum. Dis. (2001) 60:913–923.
  • ••Randomised, controlled trial ofleflunomide in RA was as effective as sulfasalazine.
  • SHARP JT, STRAND V, LEUNG H, HURLEY F, LOEW-FRIEDRICH I: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. (2000) 43:495–505.
  • ALLDRED A, EMERY P: Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother: (2001) 2:125–137.
  • KREMER JM, CALDWELL J, CANNONGW et al.: The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: A double-blind placebo controlled study. Arthritis Rheum. (2000) 43:S224.
  • •Trial of combination of leflunomide and methotrexate shown to be of benefit. Increased incidence of abnormal liver function occurred in the combination group.
  • KREMER JM: Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Sem. Arthritis Rheum. (1999) 29:14–26.
  • CVETKOVIC JT, WALLBERG-JONSSON SS: Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-lbeta, and IL-1Ra genes. J. Rheumatol (2002) 29:212–219.
  • MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552–1563.
  • •Efficacy trial of inflixirnab. The efficacy of inflixirnab was better and sustained when used with methotrexate.
  • LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl. J. Med. (2000) 343:1594-1602. ATTRACT study of combination of methotrexate and infliximab versus methotrexate alone in RA unresponsive to methotrexate alone.
  • BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl. I Med. (2000) 343:1586–1593.
  • ••Early RA trial of etanercept versusmethotrexate shows benefit with etanercept in terms of early onset of action and prevention of new erosions.
  • MORELAND LW SCHIFF MH, BAUMGARTNER SW et al: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. (1999) 130:478–486.
  • ••Etanercept benefits RA unresponsive toDMARDs.
  • WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. (1999) 340:253–259.
  • ••Etanercept added to treatment of RAunresponsive to methotrexate is beneficial compared to placebo.
  • BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–2204.
  • ••Trial of anakinra benefit in patients with RA unresponsive to DMARDs.
  • JIANG Y, GENANT HK, WATT I et al: A multicentre, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritic Rheum. (2000) 43:1001–1009.
  • •Radiological progression of RA prevented by anakinra.
  • CAMPION GV, LEBSACK ME, LOOKABAUGH J, GORDON G, CATALANO M: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritic Rheum. (1996) 39:1092–1101.
  • COHEN S, HURD E, CUSH JJ et al: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty four-week, multicentre, randomized, double-blind, placebo-controlled trial. Arthritic Rheum. (2002) 46:614–624.
  • ••Anakinra used in combination withmethotrexate significantly better than methotrexate alone in this trial.
  • WORKING PARTY OF THE BRITISH SOCIETY FOR RHEUMATOLOGY: Guidelines for prescribing TNF-a blockers in adults with rheumatoid arthritis (2001).
  • ••Guidance for using anti-TNF therapy in RA by BSR.
  • NHS HTA PROGRAMME, NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE, UK: The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab (2001).
  • NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE, UK: Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis (2002).
  • ••Guidance for using anti-TNF therapy inRA by NICE committee as per British society for rheumatology guidelines.
  • KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl. J. Med. (2001) 345:1098–1104.
  • •A study by the FDA of 70 cases of tuberculosis with infliximab in RA.
  • ARNASON BJW: TNF neutralization in MS: results of a randomized, placebo-controlled multicentre study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1999) 53:457–465.
  • KAVANAUGH A, KEENAN G, DEWOODY K et al.: Long-term follow-up of patients treated with Remicade (Infliximab) in clinical trials. ACR 65th annual scientific meeting. (2001) Poster 173.
  • •Two-year follow up with infliximab shows no increase in incidence of malignancy and lymphoma.
  • KLARESKOG L, MORELAND L, COHEN S, SANDA M, BURGE DJ: Global safety and efficacy of up to five years of Etanercept (Enbrel9 therapy. ACR 65th Annual Scientific Meeting. (2001) Abstract 150.
  • •Five-year follow up with etanercept shows no increase in incidence of malignancy and lymphoma.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.